…saved through correct diagnosis and treatment of TB [2]. However, CNS TB including TB meningitis (TBM), tends to have less favourable outcomes, particularly in cases of multidrug resistant disease or…
Content Section:
Case Reports
…are firmly committed to supporting the gMG community by providing solutions to help improve outcomes for patients and reduce the day-to-day burden of the disease. The FDA’s decision to assess…
Content Section:
News Posts
…of how to determine when and what treatment, including eligibility for disease modifying treatment and the process of “de-risking” DMTs. Session 2 The second lecture session was led by Dr…
Content Section:
Conference Reports
…is associated with a particular disease process and may be inhibited or activated by a therapy in a way that will change the course of the disease in a positive…
Content Section:
News Posts
…UK. He has a specialist interest in movement disorders and Parkinson’s disease. He is part of the national DBS service in Scotland and runs a Parkinson’s disease telemedicine service to the Western…
Content Section:
Pages
…more than 120,000 people in the UK and about 2.5 million people worldwide [1]. Significant advances have been made in MS disease-modifying therapies (DMTs) including the progressive phase [2]. However,…
Content Section:
Articles
…Britain. Upstaza is the first and only approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is…
Content Section:
News Posts
…networking. The first session focused on neurodegenerative disease, covering the spectrum from diagnosis and new individual drug treatments to prevention and understanding quality of life. Our first speaker was Professor…
Content Section:
Conference Reports
…be a significant pool of patients with undiagnosed hypopituitarism. This places an emphasis on screening to detect the disease and treat it accordingly, as highlighted in guidance published in 2017….
Content Section:
Articles